Loading...
XNAS
ALKS
Market cap4.89bUSD
Apr 04, Last price  
30.06USD
1D
-5.05%
1Q
3.51%
Jan 2017
-45.92%
Name

Alkermes Plc

Chart & Performance

D1W1MN
No data to show
P/E
13.32
P/S
3.14
EPS
2.26
Div Yield, %
—
Shrs. gr., 5y
1.50%
Rev. gr., 5y
5.87%
Revenues
1.56b
-6.36%
76,126,000166,601,000239,965,000240,717,000326,839,000178,281,000186,640,000389,977,000575,548,000618,789,000628,335,000745,694,000903,374,0001,094,274,0001,170,947,0001,038,756,0001,173,751,0001,111,795,0001,663,405,0001,557,632,000
Net income
367m
+3.18%
-73,916,0003,818,0009,445,000166,979,000130,505,000-39,626,000-45,540,000-113,678,00024,983,000-30,061,000-227,163,000-208,444,000-157,945,000-139,311,000-196,620,000-110,861,000-48,169,000-158,267,000355,757,000367,070,000
CFO
439m
+9.41%
-74,255,000116,530,00083,727,00042,424,00034,590,000-12,247,000-5,906,000-2,482,000126,551,00011,139,000-40,360,000-63,802,00019,190,00099,281,00072,077,00082,842,000101,715,00021,044,000401,353,000439,124,000
Earnings
May 30, 2025

Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
URL
https://www.alkermes.com/
IPO date
Jul 16, 1991
Employees
2,280
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,557,632
-6.36%
1,663,405
49.61%
1,111,795
-5.28%
Cost of revenue
1,135,895
1,249,283
1,202,701
Unusual Expense (Income)
NOPBT
421,737
414,122
(90,906)
NOPBT Margin
27.08%
24.90%
Operating Taxes
71,612
(97,638)
(9,037)
Tax Rate
16.98%
NOPAT
350,125
511,760
(81,869)
Net income
367,070
3.18%
355,757
-324.78%
(158,267)
228.57%
Dividends
Dividend yield
Proceeds from repurchase of equity
(200,282)
(11,714)
1,426
BB yield
4.12%
0.25%
-0.03%
Debt
Debt current
6,166
8,746
3,000
Long-term debt
144,910
444,894
395,821
Deferred revenue
10,701
Other long-term liabilities
56,019
49,878
132,213
Net debt
(673,740)
(359,738)
(472,864)
Cash flow
Cash from operating activities
439,124
401,353
21,044
CAPEX
(33,484)
(48,048)
(38,255)
Cash from investing activities
(111,308)
53,357
(64,541)
Cash from financing activities
(494,139)
(289,714)
(1,574)
FCF
352,606
345,276
(35,703)
Balance
Cash
751,668
773,491
740,075
Long term investments
73,148
39,887
131,610
Excess cash
746,934
730,208
816,095
Stockholders' equity
(976,658)
(1,344,912)
(1,708,484)
Invested Capital
2,573,192
2,969,661
3,188,421
ROIC
12.63%
16.62%
ROCE
26.42%
25.49%
EV
Common stock shares outstanding
169,198
169,730
163,541
Price
28.76
3.68%
27.74
6.16%
26.13
12.34%
Market cap
4,866,134
3.35%
4,708,310
10.18%
4,273,326
14.15%
EV
4,192,394
4,348,572
3,800,462
EBITDA
450,270
489,049
(13,044)
EV/EBITDA
9.31
8.89
Interest
22,578
23,032
13,040
Interest/NOPBT
5.35%
5.56%